JP2016506963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506963A5 JP2016506963A5 JP2015556109A JP2015556109A JP2016506963A5 JP 2016506963 A5 JP2016506963 A5 JP 2016506963A5 JP 2015556109 A JP2015556109 A JP 2015556109A JP 2015556109 A JP2015556109 A JP 2015556109A JP 2016506963 A5 JP2016506963 A5 JP 2016506963A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydropyridin
- oxo
- benzamide
- trifluoromethyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 t- butyl Chemical group 0.000 claims description 404
- 229910052736 halogen Inorganic materials 0.000 claims description 89
- 150000002367 halogens Chemical class 0.000 claims description 89
- 150000001875 compounds Chemical class 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 44
- 208000002193 Pain Diseases 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 27
- 125000002723 alicyclic group Chemical group 0.000 claims description 17
- 208000004296 neuralgia Diseases 0.000 claims description 14
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- YXHMFJXQQXHKRO-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 YXHMFJXQQXHKRO-UHFFFAOYSA-N 0.000 claims description 5
- 206010065390 Inflammatory pain Diseases 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- PRBIFBCFSMEHTE-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-phenoxybenzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC1=CC=CC=C1 PRBIFBCFSMEHTE-UHFFFAOYSA-N 0.000 claims description 4
- 208000005890 Neuroma Diseases 0.000 claims description 4
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims description 4
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- IBHSESFTJVMJEA-UHFFFAOYSA-N 4-cyano-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(C#N)=CC=C1C(=O)NC1=CC(=O)NC=C1 IBHSESFTJVMJEA-UHFFFAOYSA-N 0.000 claims description 3
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000003349 osteoarthritic effect Effects 0.000 claims description 3
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 206010003497 Asphyxia Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010021639 Incontinence Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- 208000010261 Small Fiber Neuropathy Diseases 0.000 claims description 2
- 206010073928 Small fibre neuropathy Diseases 0.000 claims description 2
- 238000011225 antiretroviral therapy Methods 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 210000000467 autonomic pathway Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000017692 primary erythermalgia Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000036262 stenosis Effects 0.000 claims description 2
- 208000037804 stenosis Diseases 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 210000003901 trigeminal nerve Anatomy 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 32
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 14
- PAMCRRDMORMCSM-UHFFFAOYSA-N n-(trifluoromethyl)benzamide Chemical compound FC(F)(F)NC(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-N 0.000 claims 10
- XNAAGHKLQDFJAV-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(1,1,2,2,2-pentafluoroethyl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(C(F)(F)C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 XNAAGHKLQDFJAV-UHFFFAOYSA-N 0.000 claims 4
- CSKLRKQUNQCFCW-UHFFFAOYSA-N 4,5-dichloro-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(Cl)=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 CSKLRKQUNQCFCW-UHFFFAOYSA-N 0.000 claims 4
- FZRXMWNNMIDCAX-UHFFFAOYSA-N 4-chloro-2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 FZRXMWNNMIDCAX-UHFFFAOYSA-N 0.000 claims 4
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims 4
- 208000004550 Postoperative Pain Diseases 0.000 claims 3
- JLOCNBNTRGBNSU-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound FC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 JLOCNBNTRGBNSU-UHFFFAOYSA-N 0.000 claims 2
- GIJKDQHCVRCMIN-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound C1=C(F)C(OC)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 GIJKDQHCVRCMIN-UHFFFAOYSA-N 0.000 claims 2
- JKAMBBDGLZFTHQ-UHFFFAOYSA-N 2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethyl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 JKAMBBDGLZFTHQ-UHFFFAOYSA-N 0.000 claims 2
- UXNUHKSSUVUOKZ-UHFFFAOYSA-N 2-(4-fluoro-2-methylphenoxy)-n-(2-oxo-1h-pyridin-4-yl)-5-(trifluoromethoxy)benzamide Chemical compound CC1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1C(=O)NC1=CC(=O)NC=C1 UXNUHKSSUVUOKZ-UHFFFAOYSA-N 0.000 claims 2
- WGJBFMMLUYGFBM-UHFFFAOYSA-N 2-[(5-fluoro-2-hydroxyphenyl)methoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound OC1=CC=C(F)C=C1COC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 WGJBFMMLUYGFBM-UHFFFAOYSA-N 0.000 claims 2
- HAHBFCDZJMZPDT-UHFFFAOYSA-N 2-[4-fluoro-2-(hydroxymethyl)phenoxy]-n-(2-oxo-1h-pyridin-4-yl)-4-(trifluoromethyl)benzamide Chemical compound OCC1=CC(F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 HAHBFCDZJMZPDT-UHFFFAOYSA-N 0.000 claims 2
- WLRVZQGFKCYIOQ-UHFFFAOYSA-N 4-chloro-2-(2-chloro-4-fluorophenoxy)-5-fluoro-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound ClC1=CC(F)=CC=C1OC1=CC(Cl)=C(F)C=C1C(=O)NC1=CC(=O)NC=C1 WLRVZQGFKCYIOQ-UHFFFAOYSA-N 0.000 claims 2
- UUAIQHMLXPMLDV-UHFFFAOYSA-N 4-chloro-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC(Cl)=CC=C1C(=O)NC1=CC(=O)NC=C1 UUAIQHMLXPMLDV-UHFFFAOYSA-N 0.000 claims 2
- CKTPSKKTZVSXLI-UHFFFAOYSA-N 4-tert-butyl-n-(2-oxo-1h-pyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-3-yl]oxybenzamide Chemical compound C=1C=C(C(F)(F)F)N=CC=1OC1=CC(C(C)(C)C)=CC=C1C(=O)NC=1C=CNC(=O)C=1 CKTPSKKTZVSXLI-UHFFFAOYSA-N 0.000 claims 2
- IDCLDFZOZFUTLI-UHFFFAOYSA-N 5-chloro-2-(4-fluoro-2-methoxyphenoxy)-n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound COC1=CC(F)=CC=C1OC1=CC=C(Cl)C=C1C(=O)NC1=CC(=O)NC=C1 IDCLDFZOZFUTLI-UHFFFAOYSA-N 0.000 claims 2
- KYRYYQRTAJIXDA-UHFFFAOYSA-N 5-fluoro-n-(2-oxo-1h-pyridin-4-yl)-2-[4-(trifluoromethoxy)phenoxy]benzamide Chemical compound C1=CNC(=O)C=C1NC(=O)C1=CC(F)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1 KYRYYQRTAJIXDA-UHFFFAOYSA-N 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 125000005921 isopentoxy group Chemical group 0.000 claims 2
- INIMUMMAVCNJFA-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)-2-[4-(trifluoromethoxy)phenoxy]-4-(trifluoromethyl)benzamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1OC1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(=O)NC=C1 INIMUMMAVCNJFA-UHFFFAOYSA-N 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 206010006074 Brachial plexus injury Diseases 0.000 claims 1
- 208000002472 Morton Neuroma Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- KXIQSNCERPESAB-UHFFFAOYSA-N n-(2-oxo-1h-pyridin-4-yl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NC=1C=CNC(=O)C=1 KXIQSNCERPESAB-UHFFFAOYSA-N 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 58
- 238000000034 method Methods 0.000 description 10
- 238000002679 ablation Methods 0.000 description 2
- PNSVJQJVGCLXPD-UHFFFAOYSA-N CC(C)(C)c1ccc(C(NC(C=C2)=CNC2=O)=O)c(Oc2ccc(C(F)(F)F)nc2)c1 Chemical compound CC(C)(C)c1ccc(C(NC(C=C2)=CNC2=O)=O)c(Oc2ccc(C(F)(F)F)nc2)c1 PNSVJQJVGCLXPD-UHFFFAOYSA-N 0.000 description 1
- FCWGDENQRAUXMY-UHFFFAOYSA-N CC1(C)C(COc(cc(C(F)(F)F)cc2)c2C(NC(C=CN2)=CC2=O)=O)C1 Chemical compound CC1(C)C(COc(cc(C(F)(F)F)cc2)c2C(NC(C=CN2)=CC2=O)=O)C1 FCWGDENQRAUXMY-UHFFFAOYSA-N 0.000 description 1
- UEAAJOBUYFZGHL-UHFFFAOYSA-N CCCOc(cccc1)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound CCCOc(cccc1)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O UEAAJOBUYFZGHL-UHFFFAOYSA-N 0.000 description 1
- CGHVTPLFSBFCMC-UHFFFAOYSA-N COc(cc1)cc(Cl)c1Oc(c(C(NC(C=CN1)=CC1=O)=O)c1)ccc1F Chemical compound COc(cc1)cc(Cl)c1Oc(c(C(NC(C=CN1)=CC1=O)=O)c1)ccc1F CGHVTPLFSBFCMC-UHFFFAOYSA-N 0.000 description 1
- GGKJOYYMGVWXAT-UHFFFAOYSA-N COc(cc1)cc(F)c1Oc(cc(C(F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound COc(cc1)cc(F)c1Oc(cc(C(F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O GGKJOYYMGVWXAT-UHFFFAOYSA-N 0.000 description 1
- ZUFQSMFAKHTNSW-UHFFFAOYSA-N COc(ccc(Oc(cc(C(C(F)(F)F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O)c1)c1F Chemical compound COc(ccc(Oc(cc(C(C(F)(F)F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O)c1)c1F ZUFQSMFAKHTNSW-UHFFFAOYSA-N 0.000 description 1
- OMKAJNDPKOXDJE-UHFFFAOYSA-N COc(cccc1F)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound COc(cccc1F)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O OMKAJNDPKOXDJE-UHFFFAOYSA-N 0.000 description 1
- GOHNZFHVWZRGGX-UHFFFAOYSA-N Cc(cc(cc1)OC)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound Cc(cc(cc1)OC)c1Oc(ccc(C(F)(F)F)c1)c1C(NC(C=CN1)=CC1=O)=O GOHNZFHVWZRGGX-UHFFFAOYSA-N 0.000 description 1
- IQNGIYJIIGTIOM-UHFFFAOYSA-N Cc(cc1)ccc1Oc(c(C(NC(C=CN1)=CC1=O)=O)c1)ccc1OC(F)(F)F Chemical compound Cc(cc1)ccc1Oc(c(C(NC(C=CN1)=CC1=O)=O)c1)ccc1OC(F)(F)F IQNGIYJIIGTIOM-UHFFFAOYSA-N 0.000 description 1
- PIQAUSNVLROXMR-UHFFFAOYSA-N Cc(cccc1)c1Oc1ccc(C(F)(F)F)cc1C(NC(C=CN1)=CC1=O)=O Chemical compound Cc(cccc1)c1Oc1ccc(C(F)(F)F)cc1C(NC(C=CN1)=CC1=O)=O PIQAUSNVLROXMR-UHFFFAOYSA-N 0.000 description 1
- FNYNPPMOZIJFAC-UHFFFAOYSA-N Cc1ncccc1Oc(cc(C(F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O Chemical compound Cc1ncccc1Oc(cc(C(F)(F)F)cc1)c1C(NC(C=CN1)=CC1=O)=O FNYNPPMOZIJFAC-UHFFFAOYSA-N 0.000 description 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 description 1
- FPKSPIQOEJACSE-UHFFFAOYSA-N O=C(c(c(C(F)(F)F)cc(C(F)(F)F)c1)c1Oc(c(F)c1)ccc1F)NC(C=CN1)=CC1=O Chemical compound O=C(c(c(C(F)(F)F)cc(C(F)(F)F)c1)c1Oc(c(F)c1)ccc1F)NC(C=CN1)=CC1=O FPKSPIQOEJACSE-UHFFFAOYSA-N 0.000 description 1
- CBWXHMITTMOYOY-UHFFFAOYSA-N O=C(c(cc(C(F)(F)F)cc1)c1Oc(cccc1)c1Cl)NC(C=CN1)=CC1=O Chemical compound O=C(c(cc(C(F)(F)F)cc1)c1Oc(cccc1)c1Cl)NC(C=CN1)=CC1=O CBWXHMITTMOYOY-UHFFFAOYSA-N 0.000 description 1
- XBCPDKDJZGECMM-UHFFFAOYSA-N O=C(c(cc(cc1)F)c1Oc(cc1)ccc1OCC1CC1)NC(C=CN1)=CC1=O Chemical compound O=C(c(cc(cc1)F)c1Oc(cc1)ccc1OCC1CC1)NC(C=CN1)=CC1=O XBCPDKDJZGECMM-UHFFFAOYSA-N 0.000 description 1
- DITZNZYXKSFLJE-UHFFFAOYSA-N O=C(c(ccc(C(F)(F)F)c1)c1OC1CCCCC1)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(C(F)(F)F)c1)c1OC1CCCCC1)NC(C=CN1)=CC1=O DITZNZYXKSFLJE-UHFFFAOYSA-N 0.000 description 1
- OFVXFYHEMPXWQX-UHFFFAOYSA-N O=C(c(ccc(C(F)(F)F)c1)c1OCCCC(F)(F)F)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(C(F)(F)F)c1)c1OCCCC(F)(F)F)NC(C=CN1)=CC1=O OFVXFYHEMPXWQX-UHFFFAOYSA-N 0.000 description 1
- REFSPUPAKCCVAD-QRUKAPELSA-N O=C(c(ccc(C(F)(F)F)c1)c1O[C@H]1C(CC2)C[C@H]2C1)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(C(F)(F)F)c1)c1O[C@H]1C(CC2)C[C@H]2C1)NC(C=CN1)=CC1=O REFSPUPAKCCVAD-QRUKAPELSA-N 0.000 description 1
- LVBOJKUDPCHPOK-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1OCCCC(F)(F)F)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1OCCCC(F)(F)F)NC(C=CN1)=CC1=O LVBOJKUDPCHPOK-UHFFFAOYSA-N 0.000 description 1
- UTKZKXRKSFATLD-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1Oc(c(F)c1)ccc1F)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1Oc(c(F)c1)ccc1F)NC(C=CN1)=CC1=O UTKZKXRKSFATLD-UHFFFAOYSA-N 0.000 description 1
- ZSNOWMCACAKMOG-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1Oc(c(F)ccc1)c1Cl)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1Oc(c(F)ccc1)c1Cl)NC(C=CN1)=CC1=O ZSNOWMCACAKMOG-UHFFFAOYSA-N 0.000 description 1
- VZVFDJLFHJSULP-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1Oc(c(F)ccc1)c1F)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1Oc(c(F)ccc1)c1F)NC(C=CN1)=CC1=O VZVFDJLFHJSULP-UHFFFAOYSA-N 0.000 description 1
- NECWBBPMTPYKFR-UHFFFAOYSA-N O=C(c(ccc(Cl)c1)c1Oc1ccc(C(F)(F)F)nc1)NC(C=CN1)=CC1=O Chemical compound O=C(c(ccc(Cl)c1)c1Oc1ccc(C(F)(F)F)nc1)NC(C=CN1)=CC1=O NECWBBPMTPYKFR-UHFFFAOYSA-N 0.000 description 1
- XNISXOXNXGRBGI-BVUQATHDSA-N O=C(c1cc(C(F)(F)F)ccc1OC1C[C@H](C2)[C@H]2C1)NC(C=CN1)=CC1=O Chemical compound O=C(c1cc(C(F)(F)F)ccc1OC1C[C@H](C2)[C@H]2C1)NC(C=CN1)=CC1=O XNISXOXNXGRBGI-BVUQATHDSA-N 0.000 description 1
- CUVYLUQYLWTAQS-UHFFFAOYSA-N O=C(c1cc(OC(F)(F)F)ccc1OCC1CCCC1)NC(C=CN1)=CC1=O Chemical compound O=C(c1cc(OC(F)(F)F)ccc1OCC1CCCC1)NC(C=CN1)=CC1=O CUVYLUQYLWTAQS-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759059P | 2013-01-31 | 2013-01-31 | |
| US61/759,059 | 2013-01-31 | ||
| PCT/US2014/013652 WO2014120808A1 (en) | 2013-01-31 | 2014-01-29 | Pyridone amides as modulators of sodium channels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018027902A Division JP6741704B2 (ja) | 2013-01-31 | 2018-02-20 | ナトリウムチャネルの調節剤としてのピリドンアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506963A JP2016506963A (ja) | 2016-03-07 |
| JP2016506963A5 true JP2016506963A5 (enExample) | 2017-03-09 |
| JP6389194B2 JP6389194B2 (ja) | 2018-09-12 |
Family
ID=50073531
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556109A Active JP6389194B2 (ja) | 2013-01-31 | 2014-01-29 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2018027902A Active JP6741704B2 (ja) | 2013-01-31 | 2018-02-20 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2019056505A Withdrawn JP2019089861A (ja) | 2013-01-31 | 2019-03-25 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2020169731A Pending JP2021001232A (ja) | 2013-01-31 | 2020-10-07 | ナトリウムチャネルの調節剤としてのピリドンアミド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018027902A Active JP6741704B2 (ja) | 2013-01-31 | 2018-02-20 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2019056505A Withdrawn JP2019089861A (ja) | 2013-01-31 | 2019-03-25 | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2020169731A Pending JP2021001232A (ja) | 2013-01-31 | 2020-10-07 | ナトリウムチャネルの調節剤としてのピリドンアミド |
Country Status (34)
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014005304A (es) | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| KR102226587B1 (ko) | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
| CN105263490B (zh) | 2013-03-14 | 2018-05-22 | 基因泰克公司 | 取代的三唑并吡啶及其使用方法 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのスルホンアミド |
| JP6383418B2 (ja) | 2013-11-27 | 2018-08-29 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| SG11201604477SA (en) | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
| MA42118A (fr) | 2015-05-22 | 2018-03-28 | Genentech Inc | Benzamides substitués et leurs méthodes d'utilisation |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP6987746B2 (ja) | 2015-09-28 | 2022-01-05 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| US10899732B2 (en) | 2015-11-25 | 2021-01-26 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| CA3013988A1 (en) | 2016-02-15 | 2017-08-24 | Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh | Taf1 inhibitors for the therapy of cancer |
| US20170239183A1 (en) * | 2016-02-23 | 2017-08-24 | PixarBio Corporation | COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| BR112019007763A2 (pt) | 2016-10-17 | 2019-07-02 | Genentech Inc | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção |
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| KR102714561B1 (ko) * | 2017-05-16 | 2024-10-10 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭 |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| WO2019191702A1 (en) | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Substituted hydro-pyrido-azines as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| GEAP202315648A (en) | 2018-11-02 | 2023-07-25 | Merck Sharp & Dohme Llc | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| WO2020092187A1 (en) | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors |
| WO2020140959A1 (zh) * | 2019-01-04 | 2020-07-09 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类衍生物、其制备方法及其在医药上的应用 |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020151728A1 (zh) * | 2019-01-25 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| WO2020169042A1 (zh) * | 2019-02-20 | 2020-08-27 | 江苏恒瑞医药股份有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| WO2021018165A1 (zh) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| TW202115038A (zh) * | 2019-08-19 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用 |
| CN112390745B (zh) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
| KR20220101606A (ko) * | 2019-09-12 | 2022-07-19 | 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 | 피리딘 산질화물 및 이의 제조 방법과 용도 |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| CN113045487B (zh) * | 2019-12-27 | 2025-01-17 | 明慧医药（上海）有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| KR20230026404A (ko) | 2020-06-17 | 2023-02-24 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드 |
| US11802122B2 (en) | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| CN111808019B (zh) * | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
| CN114031518B (zh) | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
| EP4334293A1 (en) | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| SMT202600064T1 (it) | 2021-06-04 | 2026-03-09 | Vertex Pharma | Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| CA3221939A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| UY39882A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
| UY39881A (es) | 2021-08-02 | 2023-06-15 | Eurofarma Laboratorios S A | “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS” |
| CN116655497B (zh) * | 2022-02-25 | 2025-06-03 | 中国科学院上海药物研究所 | 脒类衍生化合物及其制备方法和用途 |
| IL316422A (en) | 2022-04-22 | 2024-12-01 | Vertex Pharma | Heteroaryl compounds for pain treatment |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CN116947713B (zh) * | 2022-04-25 | 2026-03-27 | 中国科学院上海药物研究所 | 并环类化合物及其应用 |
| CA3256486A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management |
| KR20250120351A (ko) | 2022-12-06 | 2025-08-08 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법 |
| PY2404093A (es) | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits |
| AR131715A1 (es) | 2023-01-30 | 2025-04-23 | Eurofarma Laboratorios S A | AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS |
| PY2404641A (es) | 2023-01-30 | 2024-10-03 | Eurofarma Laboratorios S A | COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS |
| WO2024159287A1 (pt) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Hidroxamatos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
| WO2024159285A1 (pt) | 2023-01-30 | 2024-08-08 | Eurofarma Laboratórios S.A. | Compostos aril piridinas bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits |
| WO2024217344A1 (zh) | 2023-04-19 | 2024-10-24 | 中国科学院上海药物研究所 | Nav1.8抑制剂及其制备方法和用途 |
| KR20260116141A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료용 화합물 및 이의 고체 형태의 제조방법 |
| KR20260116140A (ko) | 2023-10-23 | 2026-07-28 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| KR20260118418A (ko) | 2023-10-23 | 2026-07-30 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| AU2024393245A1 (en) | 2023-12-07 | 2026-06-18 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| AU2025211735A1 (en) | 2024-01-24 | 2026-07-16 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
| TW202606663A (zh) | 2024-06-28 | 2026-02-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| LU605402B1 (en) | 2024-07-11 | 2026-07-14 | Sea4Us Biotecnologia E Recursos Marinhos Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
| WO2026102309A1 (en) | 2024-11-07 | 2026-05-15 | Lutroo Imaging, Llc | Selective radiotracers and methods of use |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH598252A5 (enExample) * | 1974-01-04 | 1978-04-28 | Hoffmann La Roche | |
| GB1447583A (en) * | 1974-02-04 | 1976-08-25 | Ici Ltd | Xanthene derivatives |
| US4086350A (en) * | 1974-11-06 | 1978-04-25 | Smithkline Corporation | Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms |
| GB1543964A (en) * | 1976-04-08 | 1979-04-11 | Ici Ltd | Method of antagonising herbicides on soyabean and cotton |
| US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| JP3285391B2 (ja) * | 1992-09-01 | 2002-05-27 | 日本化学工業株式会社 | ２−フェノキシ安息香酸の製造法 |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| AU7712000A (en) | 1999-09-24 | 2001-04-24 | Johns Hopkins University School Of Medicine, The | Methods for identifying an agent that corrects defective protein folding |
| JP2003034671A (ja) * | 2001-05-17 | 2003-02-07 | Nippon Nohyaku Co Ltd | ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法 |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| KR20060073930A (ko) * | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| CA2536870C (en) * | 2003-09-03 | 2009-10-27 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| WO2006011050A2 (en) | 2004-07-23 | 2006-02-02 | Pfizer Limited | Pyridine derivatives |
| WO2006133459A1 (en) | 2005-06-09 | 2006-12-14 | Vertex Pharmaceuticals Incorporated | Indane derivatives as modulators of ion channels |
| ZA200802977B (en) | 2005-09-09 | 2009-08-26 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| US7683083B2 (en) | 2005-10-12 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| MX2008013194A (es) | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| EA015952B1 (ru) * | 2007-05-03 | 2011-12-30 | Пфайзер Лимитед | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| CA2701946A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| MX2010003864A (es) * | 2007-10-11 | 2010-06-01 | Vertex Pharma | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
| EP2212290B1 (en) * | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| EP2215048B1 (en) * | 2007-10-31 | 2015-10-28 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
| JP5405592B2 (ja) * | 2008-12-23 | 2014-02-05 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ７モジュレーターとしてのジヒドロピリドンアミド |
| KR101605061B1 (ko) * | 2009-05-29 | 2016-03-21 | 라퀄리아 파마 인코포레이티드 | 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체 |
| TW201103904A (en) * | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| MX2012010658A (es) * | 2010-03-15 | 2012-12-05 | Amgen Inc | Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa. |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| US8999967B2 (en) * | 2010-09-29 | 2015-04-07 | Presidio Pharmaceuticals, Inc. | Tricyclic fused ring inhibitors of hepatitis C |
| KR101923367B1 (ko) | 2011-02-02 | 2018-12-04 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드 |
| WO2012112462A1 (en) * | 2011-02-15 | 2012-08-23 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
| WO2012112743A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| WO2012122716A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| SG193932A1 (en) * | 2011-03-29 | 2013-11-29 | Sanofi Sa | Otamixaban formulations with improved stability |
| JP5730398B2 (ja) | 2011-08-10 | 2015-06-10 | 三菱電機株式会社 | 誘導加熱調理器及びそのプログラム |
| CN102584774B (zh) * | 2011-12-22 | 2014-08-06 | 合肥工业大学 | 一种呫吨酮类衍生物及其用途 |
| CA2863892C (en) | 2012-03-06 | 2016-08-30 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| CN102659628B (zh) * | 2012-04-26 | 2014-07-02 | 四川大学 | 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂 |
| KR102226587B1 (ko) | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
| TWI606048B (zh) | 2013-01-31 | 2017-11-21 | 帝人製藥股份有限公司 | 唑苯衍生物 |
| BR112015018284B1 (pt) | 2013-01-31 | 2023-03-07 | Vertex Pharmaceuticals Incorporated | Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica |
| CN105026373B (zh) | 2013-01-31 | 2018-03-30 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的吡啶酮酰胺 |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのスルホンアミド |
| SG11201604477SA (en) | 2013-12-13 | 2016-07-28 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
-
2014
- 2014-01-29 CN CN201480011392.XA patent/CN105026373B/zh active Active
- 2014-01-29 UA UAA201508443A patent/UA120589C2/uk unknown
- 2014-01-29 GE GEAP201413922A patent/GEP20217286B/en unknown
- 2014-01-29 CN CN201810153601.4A patent/CN108164457B/zh active Active
- 2014-01-29 SG SG11201505953TA patent/SG11201505953TA/en unknown
- 2014-01-29 LT LTEP17152492.9T patent/LT3239134T/lt unknown
- 2014-01-29 PT PT147040539T patent/PT2953931T/pt unknown
- 2014-01-29 SI SI201431756T patent/SI3239134T1/sl unknown
- 2014-01-29 PL PL14704053T patent/PL2953931T3/pl unknown
- 2014-01-29 NZ NZ750187A patent/NZ750187A/en unknown
- 2014-01-29 PE PE2015001572A patent/PE20151781A1/es active IP Right Grant
- 2014-01-29 WO PCT/US2014/013652 patent/WO2014120808A1/en not_active Ceased
- 2014-01-29 GE GEAP202014909A patent/GEAP202014909A/en unknown
- 2014-01-29 JP JP2015556109A patent/JP6389194B2/ja active Active
- 2014-01-29 TW TW103103691A patent/TWI655187B/zh active
- 2014-01-29 EP EP17152492.9A patent/EP3239134B1/en active Active
- 2014-01-29 AU AU2014212509A patent/AU2014212509B2/en active Active
- 2014-01-29 KR KR1020157023601A patent/KR102227592B1/ko active Active
- 2014-01-29 AP AP2015008633A patent/AP2015008633A0/xx unknown
- 2014-01-29 US US14/167,759 patent/US9051270B2/en active Active
- 2014-01-29 SM SM20170256T patent/SMT201700256T1/it unknown
- 2014-01-29 RS RS20210235A patent/RS61503B1/sr unknown
- 2014-01-29 ES ES14704053T patent/ES2626555T3/es active Active
- 2014-01-29 SM SM20210030T patent/SMT202100030T1/it unknown
- 2014-01-29 UY UY0001035288A patent/UY35288A/es active IP Right Grant
- 2014-01-29 HU HUE14704053A patent/HUE033370T2/en unknown
- 2014-01-29 SG SG10201706206PA patent/SG10201706206PA/en unknown
- 2014-01-29 HU HUE17152492A patent/HUE053448T2/hu unknown
- 2014-01-29 TW TW108105717A patent/TWI714967B/zh active
- 2014-01-29 MX MX2015009602A patent/MX383688B/es unknown
- 2014-01-29 RU RU2015136795A patent/RU2662223C2/ru active
- 2014-01-29 DK DK17152492.9T patent/DK3239134T3/da active
- 2014-01-29 BR BR112015018289A patent/BR112015018289A2/pt not_active Application Discontinuation
- 2014-01-29 LT LTEP14704053.9T patent/LT2953931T/lt unknown
- 2014-01-29 CA CA2898866A patent/CA2898866C/en active Active
- 2014-01-29 GE GEAP202113922A patent/GEAP202113922A/en unknown
- 2014-01-29 SI SI201430220T patent/SI2953931T1/sl unknown
- 2014-01-29 AR ARP140100281A patent/AR094667A1/es active IP Right Grant
- 2014-01-29 PL PL17152492T patent/PL3239134T3/pl unknown
- 2014-01-29 MX MX2021003687A patent/MX2021003687A/es unknown
- 2014-01-29 ES ES17152492T patent/ES2857687T3/es active Active
- 2014-01-29 GE GEAP201414909A patent/GEP20207177B/en unknown
- 2014-01-29 EP EP14704053.9A patent/EP2953931B1/en active Active
- 2014-01-29 NZ NZ710270A patent/NZ710270A/en unknown
- 2014-01-29 EP EP20216557.7A patent/EP3865475A1/en active Pending
- 2014-01-29 PE PE2019001687A patent/PE20191495A1/es unknown
- 2014-01-29 HR HRP20170787TT patent/HRP20170787T1/hr unknown
- 2014-01-29 KR KR1020217007028A patent/KR102295748B1/ko active Active
- 2014-01-29 PT PT171524929T patent/PT3239134T/pt unknown
- 2014-01-29 RS RS20170516A patent/RS56015B1/sr unknown
- 2014-01-29 IL IL269964A patent/IL269964B2/en unknown
- 2014-01-29 DK DK14704053.9T patent/DK2953931T3/en active
-
2015
- 2015-04-29 US US14/699,437 patent/US9393235B2/en active Active
- 2015-07-27 PH PH12015501661A patent/PH12015501661B1/en unknown
- 2015-07-28 IL IL24019515A patent/IL240195B/en active IP Right Grant
- 2015-07-31 CL CL2015002147A patent/CL2015002147A1/es unknown
-
2016
- 2016-06-06 US US15/174,896 patent/US9758483B2/en active Active
-
2017
- 2017-05-31 CY CY20171100560T patent/CY1119163T1/el unknown
- 2017-08-03 US US15/667,722 patent/US10087143B2/en active Active
-
2018
- 2018-02-20 JP JP2018027902A patent/JP6741704B2/ja active Active
- 2018-08-09 AU AU2018214105A patent/AU2018214105B9/en active Active
- 2018-08-21 US US16/107,109 patent/US10738009B2/en active Active
-
2019
- 2019-03-25 JP JP2019056505A patent/JP2019089861A/ja not_active Withdrawn
-
2020
- 2020-06-24 US US16/910,965 patent/US11673864B2/en active Active
- 2020-07-02 AU AU2020204425A patent/AU2020204425A1/en not_active Abandoned
- 2020-10-07 JP JP2020169731A patent/JP2021001232A/ja active Pending
-
2021
- 2021-03-01 HR HRP20210349TT patent/HRP20210349T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210349T1 (hr) | Piridon amidi kao modulatori natrijevih kanala | |
| JP2016508500A5 (enExample) | ||
| JP2016525122A5 (enExample) | ||
| RU2016105511A (ru) | Сульфонамиды в качестве молдуляторов натриевых каналов | |
| RU2015136779A (ru) | Амиды в качестве модуляторов натриевых каналов | |
| RU2015136770A (ru) | Хинолинамиды и хиназолинамиды в качестве модуляторов натриевых каналов | |
| JP2021532124A5 (enExample) | ||
| RU2015108894A (ru) | СОЕДИНЕНИЯ 4-ГЕТЕРОАРИЛЗАМЕЩЕННОЙ БЕНЗОЙНОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ | |
| JP2018517746A5 (enExample) | ||
| JP2020526561A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2008510714A5 (enExample) | ||
| CA2601508A1 (en) | Cyclopropanecarboxamide derivatives | |
| JP2017533968A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| JP2009542717A5 (enExample) | ||
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| RU2011118227A (ru) | Способ лечения рака | |
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| FI3988117T3 (fi) | Terapeuttiset vasta-aineet ja niiden käyttö | |
| JP2015526441A5 (enExample) | ||
| RU2015120216A (ru) | Ингибиторы тирозинкиназы брутона | |
| RU2015113746A (ru) | Замещенные сульфонамиды |